UTHR

Rating neutralAI MemoPost-earnings T+3

United Therapeutics

As of 2026-05-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Nebulized Tyvaso IPF sNDA planned by end of summer 2026 • 2026-08-31

Expected move: +12%

Biggest risk

The bear read is that Q1 was a real earnings miss, not just noise: Associated Press and Zacks-linked coverage said revenue missed Street forecasts and EPS came in below consensus, while some secondary coverage remained cautious after the report. Primary-source detail supports the concern because total Tyvaso revenue declined 2%, Nebulized Tyvaso fell 22%, and cost of sales was hit by a $26.8 million estimated loss tied to a commercial supply agreement for Tyvaso DPI inventory [#8-K-2026-05-06] [#10-Q-2026-05-06].

Invalidation

Break below $470 or thesis failure.

What would change my mind?

The bull read after the May 6, 2026 print is that the quarter was messy but not thesis-breaking: Tyvaso DPI still grew 9%, Orenitram grew 12%, the company kept emphasizing near-term sequential growth recovery, and the pipeline still carries two major planned filings by end of summer 2026 [#8-K-2026-05-06] [#10-Q-2026-05-06]. Secondary coverage suggests at least one analyst was willing to look through the quarter toward IPF and ralinepag optionality, but the packet does not provide enough broad revision detail to treat that as a high-conviction sentiment shift.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-08

Base target

$590

p=45%

Bull target

$700

p=30%

Bear target

$470

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings execution reset in Tyvaso franchise
The bull read after the May 6, 2026 print is that the quarter was messy but not thesis-breaking: Tyvaso DPI still grew 9%, Orenitram grew 12%, the company kept emphasizing near-term sequential growth recovery, and the pipeline still carries two major planned filings by end of summer 2026 [#8-K-2026-05-06] [#10-Q-2026-05-06].
Secondary coverage suggests at least one analyst was willing to look through the quarter toward IPF and ralinepag optionality, but the packet does not provide enough broad revision detail to treat that as a high-conviction sentiment shift.

BearKey bullets

Competitive pressure in inhaled prostacyclins remains live; management explicitly described the landscape as dynamic, and secondary analyst coverage flagged Yutrepia share-gain concerns after the print [#8-K-2026-05-06].
Core commercial execution softened in Q1 2026, with total revenue down 2% year over year and total Tyvaso revenue down 2% as Nebulized Tyvaso fell 22%, showing that franchise mix shift is not fully offsetting pressure yet [#8-K-2026-05-06].
Cost of sales rose 44% year over year, helped by a $26.8 million estimated loss from a commercial supply agreement used to maintain sufficient Tyvaso DPI inventory, which raises questions about gross-margin cleanliness even as DPI volumes grow [#10-Q-2026-05-06].

WatchKey bullets

Nebulized Tyvaso IPF sNDA planned by end of summer 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $590 (p=45%)

Bull/Bear spread: +33% / -11%

Vs latest close: Bull +33% · Base +12% · Bear -11%

Scenario probabilities

Bull Target: $700 (p=30%)Base Target: $590 (p=45%)Bear Target: $470 (p=25%)

Commentary

Post-earnings sentiment is mixed rather than clearly bullish. On May 6, 2026, trusted coverage framed the quarter as an EPS and revenue miss, and one earnings write-up said the stock was roughly flat immediately after the release; by May 7, 2026, the packet anchor had UTHR at $569.18, near the packet's median target, suggesting the market did not treat the quarter as a major break in the story. By T+3, delayed analyst reaction appears mixed and incomplete rather than decisive. With limited broad revision data in the packet and only a small target-price cushion versus the anchor, this should remain a tentative monitoring view where pipeline conviction offsets, but does not erase, earnings-quality and execution concerns.

As of 2026-05-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings execution reset in Tyvaso franchise

Scenarios

Bull Target (Scenario probability)

$700 / p=30% prob

Base Target (Scenario probability)

$590 / p=45% prob

Bear Target (Scenario probability)

$470 / p=25% prob

Price $526 as of 2026-07-30

Nearest Scenario: Bear (∆ 11%)

Targets vs latest close: Bull +33% · Base +12% · Bear -11%

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-31
Nebulized Tyvaso IPF sNDA planned by end of summer 2026
The 10-Q says TETON-1 and TETON-2 were successful, integrated analyses were supportive, and the company plans to submit an sNDA to add IPF to the Nebulized Tyvaso label by the end of summer 2026; timely filing would convert a strong clinical story into a visible regulatory milestone for the core franchise [#10-Q-2026-05-06].
Prob 80.00% • Move 8.00% • Priced-in 65.00%
EVENT2026-08-31
Ralinepag NDA planned by end of summer 2026
The 10-Q says ADVANCE OUTCOMES met its primary endpoint with a 55% reduction in risk of clinical worsening and that United Therapeutics plans to submit an NDA for ralinepag extended-release tablets by the end of summer 2026, creating a second major cardiopulmonary filing catalyst beyond Tyvaso IPF [#10-Q-2026-05-06].
Prob 75.00% • Move 9.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Post-earnings execution reset in Tyvaso franchise
2026-08-05
Q1 2026 revenue fell 2% year over year to $781.5 million and diluted EPS fell to $5.82, with Tyvaso DPI up 9% to $330.3 million but Nebulized Tyvaso down 22% to $127.2 million; management said it is focused on returning to sequential quarterly revenue growth, so the next few months are an execution test rather than a new thesis reset [#8-K-2026-05-06] [#10-Q-2026-05-06].
Prob 60% • Move 4% • Priced-in 70%

Long-term Catalysts

Months to a year

No long-term catalysts

Risks

Competitive pressure in inhaled prostacyclins remains live; management explicitly described the landscape as dynamic, and secondary analyst coverage flagged Yutrepia share-gain concerns after the print [#8-K-2026-05-06].
Core commercial execution softened in Q1 2026, with total revenue down 2% year over year and total Tyvaso revenue down 2% as Nebulized Tyvaso fell 22%, showing that franchise mix shift is not fully offsetting pressure yet [#8-K-2026-05-06].
Cost of sales rose 44% year over year, helped by a $26.8 million estimated loss from a commercial supply agreement used to maintain sufficient Tyvaso DPI inventory, which raises questions about gross-margin cleanliness even as DPI volumes grow [#10-Q-2026-05-06].
Even if Nebulized Tyvaso wins IPF approval, the 10-Q says a Medicare local coverage determination update could take well over a year after the process starts, creating reimbursement-timing risk between regulatory success and clean commercial conversion [#10-Q-2026-05-06].
Forward visibility still depends heavily on filing and approval execution for Nebulized Tyvaso IPF and ralinepag, so any slippage in end-of-summer 2026 submission timing would likely pressure sentiment [#10-Q-2026-05-06].

Peers

Symbol	Summary
INSM	Pulmonary-disease-focused biotech and the closest listed operating peer in the packet for judging how investors value specialty lung-disease execution plus late-stage pipeline conversion.
REGN	Large commercial biotech with durable cash generation and meaningful R&D optionality; useful for benchmarking how much premium the market gives proven execution with multiple development shots on goal.
INCY	Commercial-stage biopharma with a mix of established revenue and pipeline catalysts, making it a reasonable comparator for execution-sensitive valuation around product durability and new indication expansion.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-08

AI Stock Memo: UTHR - United Therapeutics - RankAlpha